Can cosentyx lower vaccine protection in certain individuals?

Can Cosentyx reduce how well vaccines work in some people?

Cosentyx contains secukinumab, a monoclonal antibody that targets interleukin-17A. By blocking this pathway, the drug suppresses parts of the immune system involved in conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

How does Cosentyx affect immune responses to vaccines?

Secukinumab inhibits IL-17A, which can weaken responses to vaccines that rely on certain immune pathways. Studies show that patients taking Cosentyx have lower antibody levels after receiving the pneumococcal vaccine compared with patients who are not on the drug. Lowered responses have also been reported with tetanus and influenza vaccines in some cases.

What does the Cosentyx prescribing information say about vaccination?

The label advises patients to receive all age-appropriate vaccines before starting Cosentyx. It recommends avoiding live vaccines during treatment and recommends considering the time point of administration of non-live vaccines in relation to the treatment.

What happens if a person gets a vaccine while on Cosentyx?

Patients on Cosentyx who receive a vaccine may still produce antibodies, but the response is weaker in some individuals. Data from clinical trials and post-marketing surveillance indicate that many patients still achieve protective antibody levels, but the part of the immune system that has been suppressed by Cosentyx can affect the timing and strength of the response.

Are there specific groups at higher risk?

Patients who are also taking methotrexate or who have been previously treated with other biologic therapies may show even lower vaccine responses. Older adults and individuals who have throughs of low serum levels of secukinumab may also be less likely to develop adequate protection.

Can live vaccines be used under Cosentyx?

Live vaccines such as MMR or varicella are recommended to be avoided during Cosentyx treatment. The drug may increase risk of infection from the vaccine strain. The timing gap between completion of live vaccine administration and Aufnahme von Cosentyx is recommended based on the duration of immunosuppression.

Can biosimilars or alternatives affect vaccine protection?

No biosimilars to secukinumab are currently available. The company that develops Cosentyx, Novartis, holds active patents listed on https://www.drugpatentwatch.com/drugs/cosentyx.